Press Releases

Date Title and Summary Additional Formats
Toggle Summary NORD Launches New Program Aimed at Providing Caregivers with Relief
Grant program established with gift from Retrophin Washington, DC and San Diego, May 20, 2019 --The National Organization for Rare Disorders (NORD) Ⓡ , the leading independent nonprofit organization representing the 25-30 million Americans living with rare diseases, has launched the Rare Caregiver
View HTML
Toggle Summary Retrophin Appoints Sandra E. Poole to Board of Directors
Ms. Poole brings more than 25 years of biopharmaceutical product development and manufacturing experience to Retrophin SAN DIEGO , May 13, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced the appointment of Sandra E. Poole to the Company's Board of Directors, effective
View HTML
Toggle Summary Retrophin Reports First Quarter 2019 Financial Results
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies FSGS and IgAN Continued quarter over quarter growth in net product sales SAN DIEGO , May 07, 2019 (GLOBE NEWSWIRE) --
View HTML
Toggle Summary Retrophin to Report First Quarter 2019 Financial Results
SAN DIEGO , April 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial
View HTML
Toggle Summary Retrophin to Present at Upcoming Investor Conferences
SAN DIEGO , March 05, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the following upcoming investor conferences in March: Cowen & Company 39 th Annual Health Care Conference Date: Tuesday, March 12, 2019
View HTML
Toggle Summary Retrophin Recognizes Rare Disease Day® 2019 and Honors People Living with Rare Disease and Their Caregivers
SAN DIEGO , Feb. 28, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today joins the National Organization for Rare Disorders (NORD), the European Organisation for Rare Diseases (EURORDIS), and others worldwide to recognize Rare Disease Day ® 2019.
View HTML
Toggle Summary Retrophin Reports Fourth Quarter and Full Year 2018 Financial Results
Top-line results from pivotal Phase 3 FORT Study in PKAN expected in 3Q 2019 Two pivotal Phase 3 studies of sparsentan progressing on-track to enable potential first-in-class treatment for both FSGS and IgAN SAN DIEGO , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc.
View HTML
Toggle Summary Retrophin to Present at the 8th Annual SVB Leerink Global Healthcare Conference
SAN DIEGO , Feb. 14, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube , Ph.D., chief executive officer, will present at the 8 th Annual SVB Leerink Global Healthcare Conference in New York City on Thursday, February 28, 2019 at 3:30 p.m. ET .
View HTML
Toggle Summary Retrophin to Report Fourth Quarter and Full Year 2018 Financial Results
SAN DIEGO , Feb. 12, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report fourth quarter and full year 2018 financial results on Tuesday, February 26, 2019 after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss
View HTML
Toggle Summary Retrophin Provides Corporate Update and 2019 Outlook
Top-line readout of pivotal FORT Study in PKAN expected 3Q19 SAN DIEGO , Jan. 07, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the fourth quarter of 2018 to be approximately
View HTML